Sanofi Presents New Hemophilia Data at ISTH Congress

Sanofi is showcasing new clinical data on the long-term efficacy and safety of its hemophilia treatments, ALTUVIIIO and fitusiran, at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok. The presentations highlight the company's ongoing work in rare blood disorders.

For ALTUVIIIO, interim results from the long-term phase 3 XTEND-ed study are being presented. These findings indicate that once-weekly ALTUVIIIO continues to offer highly effective bleed protection for adults and children with severe hemophilia A. The study also observed improvements or maintenance in joint health over a two-year period.

New data from the ATLAS phase 3 study for fitusiran reinforce its potential for prophylaxis in individuals with hemophilia A or B, including those with inhibitors. Furthermore, the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application for review for fitusiran, with a decision expected by March 28, 2025.

Sanofi is delivering seven oral presentations covering its hemophilia portfolio at ISTH. The company stated these data reinforce ALTUVIIIO and fitusiran as treatments that provide effective outcomes in multiple scenarios and can be used throughout a person's life.